Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast CancerSylvia Adams, Sandra Demaria, Luis Chiriboga et al.|Clinical Cancer Research|2012Cited by 225
A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.Kevin Kalinsky, Dawn L. Hershman, Melissa Accordino et al.|Journal of Clinical Oncology|2022Cited by 73
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their CombinationX. Cynthia, Lisa A. Carey, Vera J. Suman et al.|JAMA Oncology|2024Cited by 20
Data from Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast CancerSylvia Adams, Sandra Demaria, Lina Kozhaya et al.|Unknown|2023Cited by 0
Supplementary Figure 1 from Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast CancerSylvia Adams, Sandra Demaria, Lina Kozhaya et al.|Unknown|2023Cited by 0